These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32461350)

  • 1. Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes.
    Raaijmakers TK; van den Bijgaart RJE; den Brok MH; Wassink M; de Graaf A; Wagenaars JA; Nierkens S; Ansems M; Scheffer GJ; Adema GJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction.
    den Brok MH; Nierkens S; Wagenaars JA; Ruers TJ; Schrier CC; Rijke EO; Adema GJ
    Vaccine; 2012 Jan; 30(4):737-44. PubMed ID: 22138178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Application of Cytidyl Guanosyl Oligodeoxynucleotide Can Affect the Antitumor Immune Response Induced by a Combined Protocol of Cryoablation and Dendritic Cells in Lewis Lung Cancer Model.
    Zhang M; Yin T; Lu Y; Feng H
    Med Sci Monit; 2016 Apr; 22():1309-17. PubMed ID: 27092689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides.
    Hiraoka K; Yamamoto S; Otsuru S; Nakai S; Tamai K; Morishita R; Ogihara T; Kaneda Y
    J Immunol; 2004 Oct; 173(7):4297-307. PubMed ID: 15383558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
    den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
    Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
    Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
    J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation.
    den Brok MH; Büll C; Wassink M; de Graaf AM; Wagenaars JA; Minderman M; Thakur M; Amigorena S; Rijke EO; Schrier CC; Adema GJ
    Nat Commun; 2016 Nov; 7():13324. PubMed ID: 27819292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity.
    Alteber Z; Azulay M; Cafri G; Vadai E; Tzehoval E; Eisenbach L
    Cancer Immunol Immunother; 2014 Apr; 63(4):369-80. PubMed ID: 24452202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
    Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
    Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis.
    Zonneveld-Huijssoon E; van Wijk F; Roord S; Delemarre E; Meerding J; de Jager W; Klein M; Raz E; Albani S; Kuis W; Boes M; Prakken BJ
    Ann Rheum Dis; 2012 Oct; 71(10):1706-15. PubMed ID: 22562976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
    Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
    Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microdosed Lipid-Coated (67)Ga-Magnetite Enhances Antigen-Specific Immunity by Image Tracked Delivery of Antigen and CpG to Lymph Nodes.
    Ruiz-de-Angulo A; Zabaleta A; Gómez-Vallejo V; Llop J; Mareque-Rivas JC
    ACS Nano; 2016 Jan; 10(1):1602-18. PubMed ID: 26678549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective anti-mycobacterial T cell responses through exquisite in vivo activation of vaccine-targeted dendritic cells.
    Kamath AT; Valenti MP; Rochat AF; Agger EM; Lingnau K; von Gabain A; Andersen P; Lambert PH; Siegrist CA
    Eur J Immunol; 2008 May; 38(5):1247-56. PubMed ID: 18412160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer.
    Wang HL; Xu H; Lu WH; Zhu L; Yu YH; Hong FZ
    Arch Gynecol Obstet; 2014 Jan; 289(1):155-62. PubMed ID: 23912529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.